DK2099796T3 - Aza-indolyl-forbindelser og fremgangsmåder for anvendelse - Google Patents

Aza-indolyl-forbindelser og fremgangsmåder for anvendelse

Info

Publication number
DK2099796T3
DK2099796T3 DK07854844.3T DK07854844T DK2099796T3 DK 2099796 T3 DK2099796 T3 DK 2099796T3 DK 07854844 T DK07854844 T DK 07854844T DK 2099796 T3 DK2099796 T3 DK 2099796T3
Authority
DK
Denmark
Prior art keywords
aza
methods
indolyl compounds
indolyl
compounds
Prior art date
Application number
DK07854844.3T
Other languages
Danish (da)
English (en)
Inventor
Simon Charles Goodacre
Karen Williams
Stephen Price
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Wendy Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2099796T3 publication Critical patent/DK2099796T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07854844.3T 2006-11-30 2007-11-29 Aza-indolyl-forbindelser og fremgangsmåder for anvendelse DK2099796T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (1)

Publication Number Publication Date
DK2099796T3 true DK2099796T3 (da) 2011-09-05

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07854844.3T DK2099796T3 (da) 2006-11-30 2007-11-29 Aza-indolyl-forbindelser og fremgangsmåder for anvendelse

Country Status (14)

Country Link
US (1) US7855216B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099796B1 (cg-RX-API-DMAC7.html)
JP (1) JP5211063B2 (cg-RX-API-DMAC7.html)
AR (1) AR064031A1 (cg-RX-API-DMAC7.html)
AT (1) ATE511509T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007325123B2 (cg-RX-API-DMAC7.html)
CA (1) CA2672327A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003444A1 (cg-RX-API-DMAC7.html)
DK (1) DK2099796T3 (cg-RX-API-DMAC7.html)
PE (1) PE20081354A1 (cg-RX-API-DMAC7.html)
PL (1) PL2099796T3 (cg-RX-API-DMAC7.html)
PT (1) PT2099796E (cg-RX-API-DMAC7.html)
TW (1) TW200829586A (cg-RX-API-DMAC7.html)
WO (1) WO2008067481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297070A2 (en) * 2008-07-03 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
CN103153063B (zh) 2010-07-30 2016-02-17 肿瘤疗法科学股份有限公司 喹啉衍生物及含有其的melk抑制剂
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
PL3624796T3 (pl) 2017-05-19 2025-06-30 Nflection Therapeutics, Inc. Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych
DK3624795T3 (da) 2017-05-19 2022-05-23 Nflection Therapeutics Inc Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CA3120352A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12310950B2 (en) 2021-11-23 2025-05-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
CA3247162A1 (en) * 2022-01-28 2023-08-03 Insilico Medicine Ip Limited Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
WO2023166450A1 (ko) * 2022-03-04 2023-09-07 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20250067072A (ko) * 2023-11-07 2025-05-14 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2330628T3 (es) * 2002-04-23 2009-12-14 Aventis Pharmaceuticals Inc. Ester del acido 3-(amino sustituido)-1h-indol-2-carboxilico y derivados del ester del acido 3-(amino sustituido)-benzo(b)tiofeno-2-carboxilico como imhibidores de expresion del gen de interleucina-4.
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
WO2008067481A1 (en) 2008-06-05
JP5211063B2 (ja) 2013-06-12
PE20081354A1 (es) 2008-11-14
EP2099796B1 (en) 2011-06-01
PT2099796E (pt) 2011-09-06
CA2672327A1 (en) 2008-06-05
PL2099796T3 (pl) 2011-10-31
AU2007325123B2 (en) 2012-12-13
ATE511509T1 (de) 2011-06-15
CL2007003444A1 (es) 2008-06-27
JP2010511626A (ja) 2010-04-15
US7855216B2 (en) 2010-12-21
AR064031A1 (es) 2009-03-04
HK1135099A1 (en) 2010-05-28
EP2099796A1 (en) 2009-09-16
TW200829586A (en) 2008-07-16
AU2007325123A1 (en) 2008-06-05
US20080242655A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2094085A4 (en) ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ZA200802822B (en) Raf inhibitor compounds and methods of use thereof
ZA200710969B (en) Raf inhibitor compounds and methods of use thereof
NO345061B1 (no) Anvendelse av DPP-IV inhibitorer
DK1802872T3 (da) Rörledning
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
EP2079544A4 (en) ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
DK2107373T3 (da) Analysechip og analysefremgangsmåde
IL185309A0 (en) Isoqunoline compounds and methods of use thereof